Latest disclosed round
Series B
- Date
- 2023-05-01
- Amount
- GBP 75.5m
- Sector
- Biotech & techbio
- Companies House
- 10028228
Series B
OMass Therapeutics
Drug discovery (native mass spectrometry / membrane protein platform)
CandidateSeries BOxford
Evidence status
Review retained
- Identity
- Candidate
- Match
- High candidate
- Operating status
- active
- Data origins
- Core directory, Growth Network, Live Chris T D1
Capital network
7 linked investors
Funding record
1 disclosed round
| Date | Stage | Amount | Investors |
|---|---|---|---|
| 2023-05-01 | Series B | £75.5M (extended with further £10M from British Patient Capital, 2023) | GV, Northpond Ventures, Sanofi Ventures, Syncona, Oxford Science Enterprises, Oxford University, British Patient Capital |
Traceability
Source trail
Funding and investor claims retain their public-source links. This is a research snapshot, not a live cap table.